Opna Bio is a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company’s broad portfolio targets multiple drivers of cancer, including a novel oncology discovery program focused on the fragile-X mental retardation protein (FMRP) and a diversified pipeline of promising oncology assets.
The Opna team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market.
Opna’s lead clinical compound, OPN-6602, a dual EP300/CBP inhibitor, is currently being studied in a first-in-human Phase 1 clinical trial in multiple myeloma patients.
The Opna team has a proven track record of scientific expertise and commercial value creation, having advanced multiple FDA-approved drugs to market.
Opna’s lead clinical compound, OPN-6602, a dual EP300/CBP inhibitor, is currently being studied in a first-in-human Phase 1 clinical trial in multiple myeloma patients.
Employees: 11-50
Total raised: $38M
Investors 2
| Date | Name | Website |
| - | Myeloma In... | myelomainv... |
| 07.12.2022 | Longitude ... | longitudec... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.11.2022 | Series A | $38M | - |
Mentions in press and media 9
| Date | Title | Description |
| 12.02.2025 | Opna Bio Receives Orphan Drug Designation for OPN-6602, an Oral EP300/CBP Bromodomain Inhibitor, for Multiple Myeloma | OPN-6602 is Currently in a Phase 1 Clinical Trial for Relapsed/Refractory Multiple Myeloma SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–February 12, 2025– Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and deve... |
| 13.11.2024 | Opna Bio Announces 2024 ASH Presentations Highlighting Interim Data from Phase 1 Combo Study of BET Inhibitor OPN-2853 with Ruxolitinib in Myelofibrosis, and Promising Preclinical Data with EP300/CBP ... | SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–November 13, 2024– Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that two abstracts have been accept... |
| 16.09.2024 | Positive clinical progress in the biotech scene | With the dosing of its first patient for lead candidate CDR404, CDR-Life has made significant clinical progress in its M-gager® portfolio for solid tumors, marking important milestones in the company’s mission to deliver innovative, antibo... |
| 26.08.2024 | Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor | Appoints Axel Bolte, MBA, MSc, to Board Director and Stephanie Oestreich, PhD, MPA, to Board Observer SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–August 26, 2024– Opna Bio announced that it has dosed the first patient with OPN-6602, a poten... |
| 10.04.2024 | Opna Bio Presents Promising Preclinical Data in Multiple Myeloma with OPN-6602 and in Malignant Mesothelioma with OPN-9840 Showing Significant Tumor Growth Inhibition at the American Association of Ca... | OPN-6602 Expected to Begin Phase 1 Clinical Study in Multiple Myeloma in Summer 2024 SAN DIEGO–(BUSINESS WIRE)–April 10, 2024– Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer the... |
| 22.11.2022 | Opna Bio Launches with $38 Million Series A Financing | |
| 22.11.2022 | Opna Bio Raises $38M in Series A Financing | Opna Bio, an Epalinges, Switzerland and San Francisco, CA-based clinical-stage biopharmaceutical company, raised $38M in Series A funding. The round was led by Longitude Capital and Northpond Ventures, with participation from Menlo Ventures... |
| 21.11.2022 | Opna Bio Launches with $38 Million Series A Financing to Advance Novel Oncology Discovery Program and Diversified Pipeline of Clinical and Preclinical Programs | Gideon Bollag, PhD, Named CEO and Board Director Broad Drug Portfolio Targets Fragile-X Mental Retardation Protein (FMRP) in Cancer, Bromo and Extra Terminal (BET) Domain Proteins, Colony-stimulating Factor 1 Receptor (CSF1R), and Additiona... |
| - | Opna Bio | “Opna Bio” |